Her2 Positive Gastric Cancer Market

DelveInsight’s ‘HER2+ Gastric Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the HER2+ Gastric Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, China, and South Korea.

 

The HER2+ Gastric Cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted HER2+ Gastric Cancer symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current HER2+ Gastric Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
  • South Korea

Study Period: 2018–2030

HER2+ Gastric Cancer Disease Understanding and Treatment Algorithm

HER2+ Gastric Cancer Overview

Gastric Cancer (GC) originates on the inner lining of stomach walls and then penetrates deeper into the stomach walls as the tumor develops. Several different types of cancer can occur in the stomach. The most common type is called adenocarcinoma. Approximately 90% of gastric cancers are adenocarcinoma.

 

The identification of human epidermal growth factor receptor-2 (HER2) biomarker overexpression in GC represented a significant step toward unraveling the molecular complexity of this disease.

 

Gastric cancer is more prevalent in men than women. Men consist of ~60% of the diagnosed cases across 7MM, China, and South Korea. GC is most prevalent in the old population above 45 years of age than other age groups. In countries with regular cancer screening like Japan and Korea, a majority of cases are diagnosed at an early stage, while in countries without screening programs like US and EU5, most of the cases are diagnosed at a severe stage.

 

HER2+ Gastric Cancer Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the HER2+ Gastric Cancer market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, Japan, China, South Korea.

 

The DelveInsight HER2+ Gastric Cancer market report thoroughly understands HER2+ Gastric Cancer symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides HER2+ Gastric Cancer treatment algorithms and treatment guidelines for HER2+ Gastric Cancer symptoms in the US, Europe, Japan, China, and South Korea.

 

The mainstay of treatment for patients diagnosed with the early-stage disease is gastrectomy (curative surgical resection). However, the survival rate of patients with advanced resectable gastric or gastroesophageal junction (GEJ) cancers remains poor despite new treatment strategies, such as perioperative chemotherapy or adjuvant chemoradiation.

 

For patients with HER2+ advanced, metastatic gastric, or GEJ cancer, ineligible for surgery, the recommended first-line therapy is trastuzumab chemotherapy in combination with cisplatin and capecitabine/5-FU.

 

GC is the third leading cause of cancer mortality in the world. In western countries, most of the patients are diagnosed when the tumor is at an unresectable stage. In this setting, systemic chemotherapy is the main treatment option. Although many single agents and combinations are active in metastatic disease, there is no internationally accepted standard of care, and survival remains poor. Therefore, new therapeutic strategies are needed. There is mounting evidence of the role of HER2 overexpression in patients with GC, and it has been solidly correlated to poor outcomes and more aggressive disease.

HER2+ Gastric Cancer Epidemiology

The HER2+ Gastric Cancer symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total incident cases of HER2+ Gastric Cancer is increasing in 7MM + China + South Korea during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted HER2+ Gastric Cancer symptoms epidemiology segmented as the Incidence of HER2+ Gastric Cancer, Gender-specific cases of HER2+ Gastric Cancer, Age-specific Cases of HER2+ Gastric Cancer, and Stage-specific cases of HER2+ Gastric Cancer. The report includes the incident scenario of HER2+ Gastric Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and South Korea from 2018 to 2030.

Country-wise HER2+ Gastric Cancer Epidemiology

The epidemiology segment also provides the HER2+ Gastric Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and South Korea.

 

The total number of incident cases of HER2+ Gastric Cancer-associated in 7MM + China + South Korea was 170,868 in 2020.

HER2+ Gastric Cancer Drug Chapters

The HER2+ Gastric Cancer report’s drug chapter segment encloses the detailed analysis of HER2+ Gastric Cancer early-stage (Phase- I, II, and III) pipeline drugs. It also helps understand the HER2+ Gastric Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

HER2+ Gastric Cancer Emerging Drug

 

Durvalumab: AstraZeneca

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of PD-L1 with PD-1 and CD80. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 blockade with durvalumab increased T-cell activation in vitro and decreased tumor size in co-engrafted human tumor and immune cell xenograft mouse models.

 

Fruquintinib: Hutchison Medipharma Limited

Fruquintinib is a highly selective small molecule drug candidate that has been shown to inhibit vascular endothelial growth factor receptor (“VEGFR”) 24 h a day via an oral dose, with lower off-target toxicities compared to other targeted therapies. Its tolerability, along with its clean drug–drug interaction profile demonstrated to date, may enable rational combination with other cancer therapies, such as in our ongoing clinical trials of fruquintinib in combination with chemotherapy and targeted therapy.

 

At an advanced stage, tumors secrete large amounts of VEGF, a protein-ligand, to stimulate the formation of excessive vasculature (angiogenesis) around the tumor to provide greater blood flow, oxygen, and

nutrients to the tumor. VEGF and VEGFR play pivotal roles in tumor-related angiogenesis, and fruquintinib inhibits the VEGF/VEGFR pathway. This represents an important therapeutic strategy in blocking the development of new blood vessels essential for tumors to grow and invade.

Products detail in the report…

HER2+ Gastric Cancer Market Outlook

The report’s HER2+ Gastric Cancer market outlook helps build a detailed comprehension of the historic, current, and forecasted HER2+ Gastric Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of HER2+ Gastric Cancer market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

 

According to DelveInsight, the HER2+ Gastric Cancer market in 7MM + China + South Korea is expected to grow in the study period 2018–2030.

 

Trastuzumab has emerged as the first targeted drug to improve overall survival when combined with chemotherapy in advanced HER2+ GC. New families of targeted drugs, including tyrosine kinase inhibitors (TKIs) such as lapatinib, mammalian target of rapamycin (mTOR) pathway inhibitors such as everolimus, heat-shock protein 90 (HSP90) inhibitors such as AUY922, HER dimerization inhibitors such as pertuzumab, and antibody-chemotherapy conjugates such as trastuzumab-emtansine (T-DM1), could offer alternative second-line treatments when trastuzumab-based first-line therapy fails.

 

Key Findings

This section includes a glimpse of the HER2+ Gastric Cancer market in 7MM, China, and South Korea.

 

HER2+ Gastric Cancer market size in the nine major markets was USD 1,138.1 million in 2020.

 

The United States Market Outlook

This section provides the total HER2+ Gastric Cancer market size and market size by therapies in the United States.

 

EU-5 Countries: Market Outlook

The total HER2+ Gastric Cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total HER2+ Gastric Cancer market Size and market Size by therapies in Japan are also mentioned

 

Japan accounts for the largest market size of HER2+ Gastric Cancer in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), the United States, China, and South Korea.

 

China Market Outlook

The total HER2+ Gastric Cancer market size and market size by therapies in China are provided in this section.

 

South Korea Market Outlook

The total HER2+ Gastric Cancer market size and market size by therapies in South Korea are provided in this section.

HER2+ Gastric Cancer Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers the HER2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

HER2+ Gastric Cancer Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses HER2+ Gastric Cancer key players involved in developing targeted therapeutics.

 

Major players include AstraZeneca, Bristol-Myers and Squibb, Bayer, and others.

 

Pipeline Development Activities

The report covers collaborations, acquisition, merger, licensing, and patent details for HER2+ Gastric Cancer emerging therapies.

Reimbursement Scenario in HER2+ Gastric Cancer

Approaching reimbursement proactively can positively impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

The high treatment costs, including chemo and other therapies, affect patients’ affordability and access to these treatment options. Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the drug price relative to the benefit it produces in treated patients.

 

The disease advocacy groups working in the area of HER2+ Gastric Cancer helps patients with medical billing, insurance coverage, and reimbursement issues. Also, financial assistance is available from both governments and pharmaceutical companies to help people who cannot afford the cost of their medications.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the HER2+ Gastric Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or HER2+ Gastric Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the HER2+ Gastric Cancer Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of HER2+ Gastric Cancer, explaining its causes, signs and symptoms, physiology, and currently available therapies.
  • Comprehensive insight has been provided into the HER2+ Gastric Cancer epidemiology and treatment in the 7MM, China, and South Korea.
  • Additionally, an all-inclusive account of both the current and emerging therapies for HER2+ Gastric Cancer is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the HER2+ Gastric Cancer market, historical and forecasted, is included in the report, covering drug outreach in the 7MM, China, and South Korea.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global HER2+ Gastric Cancer market.

Report Highlights

  • In the coming years, the HER2+ Gastric Cancer market is set to change due to the rising awareness of the disease, and the Favorable Environment for New Anti-infective Modalities; which would expand the market’s size to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HER2+ Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for HER2+ Gastric Cancer. The launch of emerging therapies will significantly impact the HER2+ Gastric Cancer market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

HER2+ Gastric Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • HER2+ Gastric Cancer Pipeline Analysis
  • HER2+ Gastric Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

HER2+ Gastric Cancer Report Key Strengths

  • 10 Years Forecast
  • 7MM + China + South Korea Coverage
  • HER2+ Gastric Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

HER2+ Gastric Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the HER2+ Gastric Cancer Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the HER2+ Gastric Cancer total market size and market size by therapies across the 7MM, China, and South Korea during the forecast period (2018–2030)?
  • What are the key findings of the market across 7MM + China + South Korea, and which country will have the largest HER2+ Gastric Cancer market Size during the forecast period (2018–2030)?
  • At what CAGR, the HER2+ Gastric Cancer market is expected to grow in 7MM + China + South Korea during the forecast period (2018–2030)?
  • What would be the HER2+ Gastric Cancer market outlook across the 7MM + China + South Korea during the forecast period (2018–2030)?
  • What would be the HER2+ Gastric Cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of HER2+ Gastric Cancer?
  • What is the historical HER2+ Gastric Cancer patient pool in nine major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, and South Korea?
  • What would be the forecasted patient pool of HER2+ Gastric Cancer in nine major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, and South Korea?
  • What will be the growth opportunities in the 7MM concerning the patient population about HER2+ Gastric Cancer?
  • Out of all nine countries, which country would have the largest incident population of HER2+ Gastric Cancer during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow in 7MM + China + South Korea during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of HER2+ Gastric Cancer along with the approved therapy?
  • What are the current treatment guidelines for treating HER2+ Gastric Cancer in the USA, Europe, Japan, China, and South Korea?
  • What are the HER2+ Gastric Cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of HER2+ Gastric Cancer?
  • How many therapies are developed by each company for the treatment of HER2+ Gastric Cancer?
  • How many emerging therapies are in the mid-stage and late stages of development to treat HER2+ Gastric Cancer?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to HER2+ Gastric Cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for HER2+ Gastric Cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for HER2+ Gastric Cancer?
  • What are the global historical and forecasted markets of HER2+ Gastric Cancer?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the HER2+ Gastric Cancer market.
  • To understand the future market competition in the HER2+ Gastric Cancer market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for HER2+ Gastric Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, and South Korea.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the HER2+ Gastric Cancer market.
  • To understand the future market competition in the HER2+ Gastric Cancer market.

1. Key Insights

2. Report Introduction

3. HER2+ Gastric Cancer Market Overview at a Glance

3.1. Market Share (%) Distribution of HER2+ Gastric Cancer in 2018

3.2. Market Share (%) Distribution of HER2+ Gastric Cancer in 2030

4. Executive Summary of HER2+ Gastric Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. HER2 expression and correlation with pathologic variables

5.3. Concordance between HER2 Overexpression and Gene Amplification

5.4. Clinical Manifestations

5.5. Risk factors

5.6. Pathogenesis

5.7. Stages of Gastric Cancer

5.8. Diagnosis

5.8.1. Diagnosis Guidelines

5.9. Treatment

5.9.1. Treatment guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM, China, and South Korea Total Incident Population of HER2+ Gastric Cancer

6.3. Epidemiology of HER2+ Gastric Cancer

6.4. The United States

6.4.1. Incident Cases of HER2+ Gastric Cancer in the United States

6.4.2. Gender-specific cases of HER2+ Gastric Cancer in the United States

6.4.3. Age-specific Cases of HER2+ Gastric Cancer in the United States

6.4.4. Stage-specific cases of HER2+ Gastric Cancer in the United States

6.5. EU5

6.5.1. Germany

6.5.2. France

6.5.3. Italy

6.5.4. Spain

6.5.5. The United Kingdom

6.6. Japan

6.6.1. Incident Cases of HER2+ Gastric Cancer in Japan

6.6.2. Gender-specific cases of HER2+ Gastric Cancer in Japan

6.6.3. Age-specific Cases of HER2+ Gastric Cancer in Japan

6.6.4. Stage-specific cases of HER2+ Gastric Cancer in Japan

6.7. China

6.7.1. Incident Cases of HER2+ Gastric Cancer in China

6.7.2. Gender-specific cases of HER2+ Gastric Cancer in China

6.7.3. Age-specific Cases of HER2+ Gastric Cancer in China

6.7.4. Stage-specific cases of HER2+ Gastric Cancer in China

6.8. South Korea

6.8.1. Incident Cases of HER2+ Gastric Cancer in South Korea

6.8.2. Gender-specific cases of HER2+ Gastric Cancer in South Korea

6.8.3. Age-specific Cases of HER2+ Gastric Cancer in South Korea

6.8.4. Stage-specific cases of HER2+ Gastric Cancer in South Korea

7. Organizations contributing towards HER2+ Gastric Cancer

8. Case Reports

9. Patient Journey

10. Marketed Therapies

10.1. HERCEPTIN (Trastuzumab): Roche

10.1.1. Product Description

10.1.2. Mechanism of Action

10.1.3. Regulatory Milestones

10.1.4. Safety and Efficacy of HERCEPTIN

10.1.5. Adverse Reactions

10.1.6. Product Profile

10.2. Apatinib: Elevar Therapeutic

10.2.1. Product Description

10.2.2. Regulatory Milestones

10.2.3. Other Development Activities

10.2.4. Safety and Efficacy

10.2.5. Adverse events

10.2.6. Product Profile

10.3. OPDIVO (Nivolumab): Bristol-Myers Squibb

10.3.1. Product Description

10.3.2. Regulatory Milestones

10.3.3. Other Developmental Activities

10.3.4. Safety and Efficacy

10.3.5. Product Profile

10.4. KEYTRUDA (Pembrolizumab): Merck

10.4.1. Product Description

10.4.2. Regulatory Milestones

10.4.3. Side Effects of Keytruda

10.4.4. Product Profile

10.5. ENHERTU: Daiichi Sankyo Inc.

10.5.1. Product Description

10.5.2. Regulatory Milestones

10.5.3. Other Development Activities

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.6. ROZLYTREK (Entrectinib): Genentech

10.6.1. Product Description

10.6.2. Regulatory Milestones

10.6.3. Other Developmental Activities

10.6.4. Safety and Efficacy

10.6.5. Product Profile

10.7. VITRAKVI (Larotrectinib): Bayer/Loxo Oncology

10.7.1. Product Description

10.7.2. Regulatory Milestones

10.7.3. Other Developmental Activities

10.7.4. Safety and Efficacy

10.7.5. Product Profile

10.8. CYRAMZA (Ramucirumab): Eli Lilly

10.8.1. Product Description

10.8.2. Regulatory Milestones

10.8.3. Other Development Activities

10.8.4. Safety and Efficacy of CYRAMZA

10.8.5. Side effects of CYRAMZA

10.8.6. Adverse Events

10.8.7. Product Profile

10.9. AIDIXI (Disitamab vedotin): Remegen Biosciences

10.9.1. Product Description

10.9.2. Regulatory Milestones

10.9.3. Other Development Activities

10.9.4. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.1.1. Other Assets in Development

11.2. IMFINZI (Durvalumab): AstraZeneca

11.2.1. Drug Description

11.2.2. Clinical Development

11.2.3. Product profile

11.3. Fruquintinib: Hutchison Medipharma Limited

11.3.1. Drug Description

11.3.2. Clinical Development

11.3.3. Product profile

11.4. KN026: Jiangsu Alphamab Biopharmaceuticals

11.4.1. Drug Description

11.4.2. Other Development Activities

11.4.3. Clinical Development

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. Catumaxomab (Removab): LintonPharm

11.5.1. Drug Description

11.5.2. Other Developmental Activities

11.5.3. Clinical Development

11.5.4. Product Profile

11.6. QL1604: Qilu Pharmaceutical Co., Ltd.

11.6.1. Drug Description

11.6.2. Clinical Development

11.6.3. Product Profile

11.7. Serplulimab (HLX10): Shanghai Henlius Biotech

11.7.1. Drug Description

11.7.2. Clinical Development

11.7.3. Product Profile

11.8. Stivarga (regorafenib): Bayer/Bristol-Myers Squibb

11.8.1. Drug Description

11.8.2. Other Developmental Activities

11.8.3. Clinical Development

11.8.4. Safety and Efficacy

11.8.5. Product Profile

11.9. Yervoy (Ipilimumab): Bristol-Myers Squibb/Ono Pharmaceutical

11.9.1. Drug Description

11.9.2. Other Developmental Activities

11.9.3. Clinical Development

11.9.4. Safety and Efficacy

11.9.5. Product Profile

11.10. Camrelizumab + Apatinib: Jiangsu HengRui Medicine

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.3. Product Profile

11.11. TUKSYA (tucatinib): Seagen

11.11.1. Drug Description

11.11.2. Other Developmental Activities

11.11.3. Clinical Development

11.11.4. Safety and Efficacy

11.11.5. Product Profile

11.12. Margetuximab + Combination therapy: MacroGenics/Zai Lab

11.12.1. Drug Description

11.12.2. Other Developmental Activities

11.12.3. Clinical Development

11.12.4. Safety and Efficacy

11.12.5. Product Profile

11.13. Lenvatinib (Lenvima): Merck Sharp & Dohme Corp.|Eisai Inc.

11.13.1. Drug Description

11.13.2. Other Development Activities

11.13.3. Clinical Development

11.13.4. Safety and Efficacy

11.13.5. Product Profile

11.14. Zenocutuzumab (MCLA-128): Merus N.V.

11.14.1. Drug Description

11.14.2. Other Development Activities

11.14.3. Clinical Development

11.14.4. Safety and Efficacy

11.14.5. Product Profile

11.15. Bavituximab: OncXerna Therapeutics, Inc.|Merck Sharp & Dohme Corp.

11.15.1. Drug Description

11.15.2. Other Development Activities

11.15.3. Clinical Development

11.15.4. Safety and Efficacy

11.15.5. Product Profile

11.16. Sintilimab (TYVYT): Innovent Biologics/Eli Lilly and Company

11.16.1. Drug Description

11.16.2. Other Development Activities

11.16.3. Clinical Development

11.16.4. Safety and Efficacy

11.16.5. Product Profile

12. HER2+ Gastric Cancer: 7MM, China, and South Korea Market Analysis

12.1. Key Findings

12.2. Market Size of HER2+ Gastric Cancer in 7MM, China, and South Korea

12.3. Market Outlook

12.4. United States Market Size

12.4.1. Total Market Size of HER2+ Gastric Cancer in the United States

12.4.2. Market Size of HER2+ Gastric Cancer by Therapies

12.5. EU-5 Market

12.5.1. Germany

12.5.2. France

12.5.3. Italy

12.5.4. Spain

12.5.5. United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of HER2+ Gastric Cancer in Japan

12.6.2. Market Size of HER2+ Gastric Cancer by Therapies in Japan

12.7. China Market Size

12.7.1. Total Market Size of HER2+ Gastric Cancer in China

12.7.2. Market Size of HER2+ Gastric Cancer by Therapies in China

12.8. South Korea Market Size

12.8.1. Total Market Size of HER2+ Gastric Cancer in South Korea

12.8.2. Market Size of HER2+ Gastric Cancer by Therapies in South Korea

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. KOL Views

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of HER2+ Gastric Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: CAP-ASCP-ASCO HER2 Testing and Clinical Decision-making in Gastroesophageal Adenocarcinoma Guidelines, 2019

Table 3: Total Incident Population of HER2+ Gastric Cancer in 7MM, China, and South Korea (2018–2030)

Table 4: Incident Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 5: Gender-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 6: Age-specific Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 7: Stage-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 8: Incident Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 9: Gender-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 10: Age-specific Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 11: Stage-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 12: Incident Cases of HER2+ Gastric Cancer in France (2018–2030)

Table 13: Gender-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Table 14: Age-specific Cases of HER2+ Gastric Cancer in France (2018–2030)

Table 15: Stage-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Table 16: Incident Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 17: Gender-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 18: Age-specific Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 19: Stage-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 20: Incident Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 21: Gender-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 22: Age-specific Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 23: Stage-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 24: Incident Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 25: Gender-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 26: Age-specific Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 27: Stage-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 28: Incident Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 29: Gender-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 30: Age-specific Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 31: Stage-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 32: Incident Cases of HER2+ Gastric Cancer in China (2018–2030)

Table 33: Gender-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Table 34: Age-specific Cases of HER2+ Gastric Cancer in China (2018–2030)

Table 35: Stage-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Table 36: Incident Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 37: Gender-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 38: Age-specific Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 39: Stage-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 40: Organizations contributing toward the Fight Against Gastric Cancer

Table 41: Durvalumab, Clinical Trial Description, 2021

Table 42: Fruquintinib, Clinical Trial Description, 2021

Table 43: KN026, Clinical Trial Description, 2021

Table 44: Catumaxomab, Clinical Trial Description, 2021

Table 45: QL1604, Clinical Trial Description, 2021

Table 46: Serplulimab, Clinical Trial Description, 2021

Table 47: Regorafenib, Clinical Trial Description, 2021

Table 48: Ipilimumab, Clinical Trial Description, 2021

Table 49: Camrelizumab + Apatinib, Clinical Trial Description, 2021

Table 50: Tucatinib, Clinical Trial Description, 2021

Table 51: Margetuximab + combination therapy, Clinical Trial Description, 2021

Table 52: Lenvatinib, Clinical Trial Description, 2021

Table 53: Zenocutuzumab, Clinical Trial Description, 2021

Table 54: Bavituximab, Clinical Trial Description, 2021

Table 55: Sintilimab, Clinical Trial Description, 2021

Table 56: 7MM, China, and South Korea Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 57: The US Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 58: The US Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 59: The Germany Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 60: The Germany Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 61: The France Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 62: The France Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 63: The Italy Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 64: The Italy Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 65: The Spain Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 66: The Spain Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 67: The United Kingdom Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 68: The United Kingdom Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 69: The Japan Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 70: The Japan Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 71: The China Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 72: The China Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

Table 73: The South Korea Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Table 74: The South Korea Market Size of HER2+ Gastric Cancer by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Manifestations of Gastric Cancer

Figure 2: Risk Factors Involved in Gastric Cancer

Figure 3: Stages of Gastric Cancer

Figure 4: HER2-testing algorithm in adenocarcinoma of the stomach and gastroesophageal junction

Figure 5: Guidelines by Japanese Society of Pathology

Figure 6: Strategies for targeting HER2-positive gastric cancer

Figure 7: Total Incident Population of HER2+ Gastric Cancer in 7MM, China, and South Korea (2018–2030)

Figure 8: Incident Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 9: Gender-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 10: Age-specific Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 11: Stage-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 12: Incident Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 13: Gender-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 14: Age-specific Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 15: Stage-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 16: Incident Cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 17: Gender-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 18: Age-specific Cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 19: Stage-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 20: Incident Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 21: Gender-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 22: Age-specific Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 23: Stage-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 24: Incident Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 25: Gender-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 26: Age-specific Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 27: Stage-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 28: Incident Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 29: Gender-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 30: Age-specific Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 31: Stage-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 32: Incident Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 33: Gender-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 34: Age-specific Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 35: Stage-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 36: Incident Cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 37: Gender-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 38: Age-specific Cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 39: Stage-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 40: Incident Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 41: Gender-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 42: Age-specific Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 43: Stage-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 44: Summary of Efficacy from ToGA Trial

Figure 45: 7MM, China, and South Korea Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 46: The US Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 47: The US Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 48: The Germany Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 49: The Germany Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 50: The France Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 51: The France Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 52: The Italy Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 53: The Italy Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 54: The Spain Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 55: The Spain Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 56: The United Kingdom Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 57: The United Kingdom Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 58: The Japan Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 59: The Japan Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 60: The China Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 61: The China Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 62: The South Korea Market Size of HER2+ Gastric Cancer in USD Million (2018–2030)

Figure 63: The South Korea Market Size of HER2+ Gastric Cancer by Therapies (2018–2030)

Figure 64: Common and Emerging Biomarkers Used in Gastric Cancer

Figure 65: Five-year Survival Rates (%) of Various Countries

• Roche

• Elevar Therapeutic

• Bristol-Myers Squibb

• Merck

• Daiichi Sankyo Inc.

• Genentech

• Bayer/Loxo Oncology

• Eli Lilly

• Remegen Biosciences

• AstraZeneca

• Hutchison Medipharma Limited

• Jiangsu Alphamab Biopharmaceuticals

• LintonPharm

• Qilu Pharmaceutical Co., Ltd.

• Shanghai Henlius Biotech

• Bayer/Bristol-Myers Squibb

• Bristol-Myers Squibb/Ono Pharmaceutical

• Jiangsu HengRui Medicine

• Seagen

• MacroGenics/Zai Lab

• Merck Sharp & Dohme Corp.|Eisai Inc.

• Merus N.V.

• OncXerna Therapeutics, Inc.|Merck Sharp & Dohme Corp.

• Innovent Biologics/Eli Lilly and Company

  • Tags:
  • HER2+ Gastric Cancer market
  • HER2+ Gastric Cancer market resear...
  • HER2+ Gastric Cancer market insigh...
  • HER2+ Gastric Cancer market trends
  • HER2+ Gastric Cancer market foreca...
  • HER2+ Gastric Cancer market share
  • HER2+ Gastric Cancer pipeline drug...
  • HER2+ Gastric Cancer treatment alg...
  • HER2+ Gastric Cancer drugs
  • HER2+ Gastric Cancer sales forecas...
  • HER2+ Gastric Cancer market size
  • HER2+ Gastric Cancer disease
  • HER2+ Gastric Cancer epidemiology
  • HER2+ Gastric Cancer

Forward to Friend

Need A Quote